[go: up one dir, main page]

WO2000023568A3 - Procedes et compositions permettant de reduire la surproduction de mitochondries des especes oxygene reactives dans les cellules - Google Patents

Procedes et compositions permettant de reduire la surproduction de mitochondries des especes oxygene reactives dans les cellules Download PDF

Info

Publication number
WO2000023568A3
WO2000023568A3 PCT/US1999/015734 US9915734W WO0023568A3 WO 2000023568 A3 WO2000023568 A3 WO 2000023568A3 US 9915734 W US9915734 W US 9915734W WO 0023568 A3 WO0023568 A3 WO 0023568A3
Authority
WO
WIPO (PCT)
Prior art keywords
overproduction
compositions
cells
methods
oxygen species
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/015734
Other languages
English (en)
Other versions
WO2000023568A2 (fr
Inventor
Michael Brownlee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2000023568A2 publication Critical patent/WO2000023568A2/fr
Publication of WO2000023568A3 publication Critical patent/WO2000023568A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ecology (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un moyen d'identification d'agents permettant de réduire les taux d'espèces oxygène réactive. Ces agents peuvent également réduire les indicateurs corrélés au taux d'espèces oxygène réactives, tels que les taux de LP, AGE, NFλB, PKC ou d'activation de l'aldose réductase dans les cellules insulino-dépendantes développées dans des conditions de forte concentration de glucose.
PCT/US1999/015734 1998-10-06 1999-07-12 Procedes et compositions permettant de reduire la surproduction de mitochondries des especes oxygene reactives dans les cellules Ceased WO2000023568A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16718298A 1998-10-06 1998-10-06
US09/167,182 1998-10-06
US30568899A 1999-05-04 1999-05-04
US09/305,688 1999-05-04

Publications (2)

Publication Number Publication Date
WO2000023568A2 WO2000023568A2 (fr) 2000-04-27
WO2000023568A3 true WO2000023568A3 (fr) 2000-09-14

Family

ID=26862926

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1999/015734 Ceased WO2000023568A2 (fr) 1998-10-06 1999-07-12 Procedes et compositions permettant de reduire la surproduction de mitochondries des especes oxygene reactives dans les cellules
PCT/US1999/023457 Ceased WO2000019993A2 (fr) 1998-10-06 1999-10-06 Methodes et compositions permettant de reduire la surproduction mitochondriale d'especes oxygenees reactives dans des cellules

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US1999/023457 Ceased WO2000019993A2 (fr) 1998-10-06 1999-10-06 Methodes et compositions permettant de reduire la surproduction mitochondriale d'especes oxygenees reactives dans des cellules

Country Status (2)

Country Link
AU (1) AU6421899A (fr)
WO (2) WO2000023568A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485721B2 (en) 2002-06-07 2009-02-03 Duke University Substituted porphyrins

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
DE60024588T2 (de) 1999-01-25 2006-08-17 National Jewish Medical And Research Center, Denver Substituierte porphyrine und deren therapeutische verwendungen
US20030032634A1 (en) 2001-06-01 2003-02-13 Piganelli Jon D. Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
FR2806911B1 (fr) * 2000-03-28 2003-01-10 Univ Rene Descartes Utilisation de mimetiques de la sod dans le traitement d'insuffisances hepatocellulaires
WO2003052067A2 (fr) * 2001-12-13 2003-06-26 University Of Virginia Patent Foundation Transfection d'organelle induite par un vecteur
SI1463563T1 (sl) 2001-12-14 2009-06-30 Alcon Inc Superoksidni dizmutazni mimetiki za zdravljenje očesnih motenj in bolezni
MXPA05005937A (es) * 2002-12-06 2005-08-18 Alcon Inc Imitaciones de superoxido de dismutasa para el tratamiento de trastornos y enfermedades oculares.
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
AU2004297533B2 (en) 2003-10-24 2010-04-29 Gencia Corporation Methods and compositions for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
BRPI0417549A (pt) 2003-12-11 2007-03-27 Alcon Inc miméticos de superóxido dismutase para o tratamento de lesão de nervo óptico e retinal
US20080015144A1 (en) * 2003-12-12 2008-01-17 Alvert Einstein College Of Medicine Of Yeshiva Uni Glp- (9-36) Methods and Compositions
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
CA2568134A1 (fr) 2004-05-24 2005-12-08 New York University Methode de traitement ou de prevention d'effets pathologiques d'augmentations aigues de l'hyperglycemie et/ou d'augmentations aigues de flux d'acides gras libres
WO2008044138A1 (fr) * 2006-10-12 2008-04-17 Syddansk Universitet Nanocapteur optique permettant la détection des espèces réactives de l'oxygène
ES2373886T3 (es) 2008-02-29 2012-02-09 Buck-Chemie Gmbh Agente adhesivo para la aplicación sobre un objeto sanitario.
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
CA2725012C (fr) 2008-05-23 2019-05-07 National Jewish Health Procedes de traitement d'une blessure associee a une exposition a une espece chimique alkylante
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
CA2922849A1 (fr) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents utiles pour le traitement de l'obesite, du diabete et de troubles associes
US9572816B2 (en) 2012-10-25 2017-02-21 Technion Research And Development Foundation Ltd. Method of treatment of disease
CN110249047A (zh) * 2016-11-14 2019-09-17 纪念斯隆-凯特琳癌症中心 使用源自干细胞的施旺细胞的药物发现方法
US11331288B2 (en) 2017-09-14 2022-05-17 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for increasing vascularity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH059114A (ja) * 1990-08-29 1993-01-19 Takeda Chem Ind Ltd 糖尿病性合併症の予防・治療剤
WO1998027426A1 (fr) * 1996-12-17 1998-06-25 University Of Aberdeen Substrats exerçant un effet sur les canaux
WO1999000123A1 (fr) * 1997-06-26 1999-01-07 Pharmacia & Upjohn Ab Utilisation d'un medicament permettant de moduler la regulation de l'upc-2 et procede de tri de medicaments potentiels contre l'obesite

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
AU3758695A (en) * 1994-09-20 1996-04-09 Duke University Oxidoreductase activity of manganic porphyrins
AU5928396A (en) * 1995-06-07 1996-12-30 Monsanto Company Process for preparing substituted polyazamacrocycles
DE69813898T2 (de) * 1997-11-03 2004-03-11 Duke University Substituierte porphyrinen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH059114A (ja) * 1990-08-29 1993-01-19 Takeda Chem Ind Ltd 糖尿病性合併症の予防・治療剤
WO1998027426A1 (fr) * 1996-12-17 1998-06-25 University Of Aberdeen Substrats exerçant un effet sur les canaux
WO1999000123A1 (fr) * 1997-06-26 1999-01-07 Pharmacia & Upjohn Ab Utilisation d'un medicament permettant de moduler la regulation de l'upc-2 et procede de tri de medicaments potentiels contre l'obesite

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CURCIO, F. AND CERIELLO, A.: "Decreased cultured endothelial cell proliferation in high glucose medium is reversed by antioxidants: new insights on the pathophysiological mechanisms of diabetic vascular complications.", IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY, vol. 28A, no. 11-12, November 1992 (1992-11-01) - December 1992 (1992-12-01), pages 787 - 790, XP000879178 *
DATABASE WPI Section Ch Week 199308, Derwent World Patents Index; Class B05, AN 1993-061598[08], XP002131312, "New drug for preventing and treating diabetic complications comprises 1,4-benzoquinone or its hydroquinone form; treats nephropathy, neuropathy, arteriosclerosis etc." *
ELLIS, E.A. ET AL.: "Increased NADH oxidase activity in the retina of the BBZ/WOR diabetic rat", FREE RADICAL BIOLOGY AND MEDICINE, vol. 24, no. 1, 1 January 1998 (1998-01-01), pages 111 - 120, XP000879172 *
GIARDINO, I. ET AL.: "BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells.", JOURNAL OF CLINICAL INVESTIGATION, vol. 97, no. 6, March 1996 (1996-03-01), pages 1422 - 1428, XP000879169 *
KING, G.L. AND BROWNLE, M.: "The cellualr and molecular mechanisms of diabetic complications", ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, vol. 25, no. 2, June 1996 (1996-06-01), pages 255 - 270, XP000878790 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485721B2 (en) 2002-06-07 2009-02-03 Duke University Substituted porphyrins

Also Published As

Publication number Publication date
WO2000019993A2 (fr) 2000-04-13
AU6421899A (en) 2000-04-26
WO2000019993A3 (fr) 2001-03-01
WO2000023568A2 (fr) 2000-04-27

Similar Documents

Publication Publication Date Title
WO2000023568A3 (fr) Procedes et compositions permettant de reduire la surproduction de mitochondries des especes oxygene reactives dans les cellules
WO2002090539A3 (fr) Compositions, methodes et trousses permettant d&#39;isoler des acides nucleiques au moyen de tensioactifs et de proteases
WO1999051142A3 (fr) Suivi non invasif du taux de glucose tissulaire
EP2266396A3 (fr) Modulation de cellules souches au moyen de proteines a doigts de zinc
WO2003069308A3 (fr) Methode de determination d&#39;une concentration d&#39;analyte dans un echantillon provenant d&#39;un spectre d&#39;absorption
WO2003053997A3 (fr) Methodes permettant d&#39;augmenter l&#39;erythropoietine endogene (epo)
WO2000028090A3 (fr) Essais diagnostiques du cancer
AU2002319780A1 (en) Alternative compositions and methods for the culture of stem cells
AU6362100A (en) Derivatized polyurethane compositions and methods of making
AU2889201A (en) Automatic water toxicity measuring apparatus
WO2005000229A3 (fr) Compositions et procedes de modulation de s-nitrosoglutathion reductase
TR200002113T2 (tr) Lisofosfatidiletanolamin (18:1) ve lisofosfatidilinositolün yaşlanmayı geçiktirmek ve meyve olgunlaşmasını artırmak için kullanımı.
WO2002008461A3 (fr) Methodes d&#39;analyse et d&#39;identification de genes transcrits et empreinte genetique
WO2004094675A3 (fr) Compositions et methodes permettant de determiner la presence de coronavirus du sras dans un echantillon
WO2001096604A3 (fr) Analyse de polymorphismes genetiques a l&#39;aide de marqueurs detectables a la lumiere diffusee
AU2001249444A1 (en) Methods and compositions for the simultaneous detection of multiple analytes
WO2000075363A3 (fr) Mesure enzymatique de l&#39;acide mycophenolique
HK1039965A1 (zh) 用於檢測cryptosporidium parvum的方法和試劑盒
WO2003066817A3 (fr) Compositions et procedes d&#39;amplification par cercle roulant
AU2001266274A1 (en) Assay techniques based on growth stage dependent expression inc. elegans
WO2002010752A3 (fr) Puces de detection a couches multiples de polysiloxane
AU1740500A (en) Thyroid peroxidase autoantibody assay compositions, method and kit
WO2004009843A3 (fr) Detection de micro-organismes
AU2001269730A1 (en) Low carbohydrate compositions, kits thereof, and methods of use
AU2001287818A1 (en) Method and installation for opening eggs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase